With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...
Vial's INHBE siRNA is a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE and its gene product, Activin E -- Leading key opinion leaders (KOL ...
A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...
SHANGHAI and SANTA BARBARA, Calif., /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, ...
California VC firm Aditum Bio is at it again, this time partnering up with China-based Mabwell Bioscience to launch a new biotech focused on cardiovascular disease. Aditum has paid Mabwell $12 million ...
Since the identification of the double-helix structure of DNA, the scientific field of genetics has developed and found applications in many diverse industries. First discovered in the late 1990s, ...
Figure 1: siRNAs administered intravaginally are efficiently taken up by vaginal tissue and durably silence endogenous EGFP expression. To investigate whether siRNAs could protect mice from HSV-2 ...
Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...
Alnylam (ALNY) announced the planned expansion of its manufacturing facility in Norton, Massachusetts. The company is preparing to invest $250M to ...
Transfecting siRNA with a high efficiency won’t be a challenge for you anymore thanks to these tips. siRNA transfection is a powerful tool to understand underlying mechanisms in gene regulation and ...
GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about oligonucleotides. The drugmaker is paying $85 million upfront to Empirico ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback